Beta Bionics, Inc. (BBNX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BBNX SEC filings page.
Beta Bionics, Inc. (BBNX) reported $119.0M in revenue over the twelve months to Jun 30, 2026, up 52.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but costs still outrun gross profit; the 2025 balance-sheet improvement was funded mainly through financing, not operations.
Revenue growth has not yet produced operating leverage: gross margin stayed near55.0% across FY2024 and FY2025, while operating margin remained around-70.0% . Additional sales were therefore largely absorbed by operating expenses instead of reaching operating profit.
The business has not reached self-funding: FY2025 operating cash flow was
At FY2025 year-end, reported cash, equivalents, and investments equaled 62.3 months of the latest annual operating outflow, a balance-sheet measure rather than an operating result. Liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Beta Bionics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Beta Bionics, Inc. held $264.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $50.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Beta Bionics, Inc. scores 70/100 among other emerging companies.
Beta Bionics, Inc. had 44M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Beta Bionics, Inc. scores 64/100 among other emerging companies.
Beta Bionics, Inc. spent $34.8M on research and development in fiscal year 2025, which was 20.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Beta Bionics, Inc. scores 52/100 among other emerging companies.
Beta Bionics, Inc. reported revenue of $100.3M in fiscal year 2025, against $65.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Beta Bionics, Inc. scores 91/100 among other emerging companies.
Beta Bionics, Inc.'s operations used $50.9M of cash in fiscal year 2025, against $48.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Beta Bionics, Inc. scores 27/100 among other emerging companies.
Beta Bionics, Inc.'s cash, cash equivalents and investments came to $264.6M at the end of fiscal year 2025, against $41.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Beta Bionics, Inc. scores 92/100 among other emerging companies.
Beta Bionics, Inc. scores 12.75, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($951.1M) relative to total liabilities ($41.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Beta Bionics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Beta Bionics, Inc. reported a net loss of $73.2M while operations used $50.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Beta Bionics, Inc. generated $32.0M in revenue in Q2 2026. This represents an increase of 37.8% from the same quarter a year earlier. Against the prior quarter it is up 15.9%.
Beta Bionics, Inc.'s EBITDA was -$24.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 5.0%.
Beta Bionics, Inc. reported -$23.4M in net income in Q2 2026. This represents a decrease of 38.7% from the same quarter a year earlier. Against the prior quarter it is down 6.9%.
Beta Bionics, Inc. earned -$0.53 per diluted share (EPS) in Q2 2026. This represents a decrease of 35.9% from the same quarter a year earlier. Against the prior quarter it is down 8.2%.
Cash & Balance Sheet
Beta Bionics, Inc. recorded an outflow of $15.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 1.9% from the same quarter a year earlier. Against the prior quarter it is up 37.9%.
Beta Bionics, Inc. held $44.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Beta Bionics, Inc.'s gross margin was 59.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.
Beta Bionics, Inc.'s operating margin was -79.9% in Q2 2026, reflecting core business profitability. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.0 percentage points.
Beta Bionics, Inc.'s net profit margin was -73.1% in Q2 2026, showing the share of revenue converted to profit. This is down 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.2 percentage points.
Beta Bionics, Inc.'s ROE was -9.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Capital Allocation
Beta Bionics, Inc. invested $10.2M in research and development in Q2 2026. This represents an increase of 15.4% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.
Beta Bionics, Inc. invested $1.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 41.6% from the same quarter a year earlier. Against the prior quarter it is down 24.5%.
Not reported for Q2 2026.
BBNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M+37.8% | $27.6M+56.6% | $32.1M+57.1% | $27.3M+63.1% | $23.2M+54.4% | $17.6M+36.4% | $20.4M | $16.7M |
| Cost of Revenue | $13.1M+22.1% | $11.2M+29.1% | $13.2M+50.6% | $12.1M+55.7% | $10.7M+54.2% | $8.7M+51.2% | $8.8M | $7.8M |
| Gross Profit | $18.9M+51.2% | $16.4M+83.2% | $18.9M+62.1% | $15.1M+69.6% | $12.5M+54.7% | $9.0M+24.6% | $11.7M | $8.9M |
| R&D Expenses | $10.2M+15.4% | $10.4M+36.4% | $10.1M+10.0% | $8.2M+59.4% | $8.9M+39.7% | $7.6M+38.5% | $9.2M | $5.1M |
| SG&A Expenses | $9.6M+21.8% | $9.6M+45.2% | $8.6M+82.7% | $7.9M+55.2% | $7.9M+73.4% | $6.6M+88.5% | $4.7M | $5.1M |
| Operating Income | -$25.6M-28.7% | -$24.3M-30.2% | -$16.1M-23.7% | -$17.0M-55.3% | -$19.9M-68.6% | -$18.6M-97.2% | -$13.0M | -$11.0M |
| EBITDA | -$24.9M-27.4% | -$23.7M-29.2% | -$15.6M-21.7% | -$16.7M-56.5% | -$19.5M-70.0% | -$18.3M-100.1% | -$12.8M | -$10.6M |
| Net Income | -$23.4M-38.7% | -$21.9M+23.6% | -$13.5M+25.6% | -$14.2M-45.9% | -$16.9M-16.6% | -$28.7M-130.2% | -$18.1M | -$9.7M |
| EPS (Basic) | -$0.53-35.9% | -$0.49+47.3% | -$0.29+89.4% | -$0.33+77.4% | -$0.39+83.5% | -$0.93+55.1% | -$2.74 | -$1.46 |
| EPS (Diluted) | -$0.53-35.9% | -$0.49+47.3% | -$0.29 | -$0.33 | -$0.39 | -$0.93 | -$2.74 | -$1.46 |
| Diluted Shares (Avg) | 45M+2.7% | 44M+44.7% | N/A | 44M | 43M | 31M | N/A | 7M |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
BBNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $292.4M-11.4% | $304.4M-9.9% | $328.7M+119.7% | $330.0M | $330.0M | $338.0M | $149.6M+36.0% | N/A |
| Current Assets | $231.0M-19.2% | $248.0M-5.3% | $267.9M+101.5% | $270.0M | $286.1M | $261.9M | $132.9M+28.3% | N/A |
| Cash & Equivalents | $44.3M+26.4% | $30.2M-28.9% | $31.6M+3.8% | $38.5M+120.2% | $35.1M+169.2% | $42.5M+92.3% | $30.4M+14.6% | $17.5M |
| Short-Term Investments | $136.2M-36.6% | $169.3M-10.4% | $187.5M+156.4% | $190.2M | $214.6M | $189.0M | $73.1M+4.2% | $0 |
| Inventory | $23.9M+38.1% | $23.7M+50.8% | $21.7M+63.1% | $20.4M | $17.3M | $15.7M | $13.3M+969.9% | N/A |
| Accounts Receivable | $18.1M+58.4% | $15.8M+73.8% | $17.1M+42.7% | $11.5M | $11.4M | $9.1M | $12.0M+169.7% | N/A |
| Long-Term Investments | $44.6M+43.3% | $39.9M-37.7% | $45.4M | $45.3M | $31.1M | $64.0M | $0 | $0 |
| Total Liabilities | $36.0M+27.1% | $33.2M+36.7% | $41.1M-89.6% | $35.3M | $28.3M | $24.3M | $395.0M+26.1% | N/A |
| Current Liabilities | $26.0M+33.5% | $23.2M+40.6% | $30.9M+46.2% | $25.4M | $19.5M | $16.5M | $21.1M+99.4% | N/A |
| Non-Current Liabilities | $10.0M+13.1% | $10.0M+28.3% | $10.2M-97.3% | $9.9M | $8.8M | $7.8M | $373.9M+23.6% | N/A |
| Total Equity | $256.4M-15.0% | $271.2M-13.5% | $287.6M+217.2% | $294.8M+228.8% | $301.6M+236.4% | $313.8M+246.4% | -$245.4M-20.8% | -$228.8M |
| Retained Earnings | -$415.2M-21.3% | -$391.8M-20.4% | -$369.9M-24.7% | -$356.5M | -$342.3M | -$325.4M | -$296.7M-29.2% | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BBNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.6M-7.6% | -$23.8M-19.3% | -$8.6M+39.6% | -$8.7M+9.2% | -$13.6M-11.1% | -$20.0M-64.5% | -$14.3M | -$9.6M |
| Depreciation & Amortization | $709K+104.3% | $585K+93.1% | $538K+131.9% | $385K+15.6% | $347K+16.1% | $303K+5.6% | $232K | $333K |
| Stock-Based Compensation | $7.0M+46.2% | $5.4M+92.8% | N/A | $4.5M+126.6% | $4.8M+220.1% | $2.8M+106.6% | N/A | $2.0M |
| Capital Expenditures | $1.0M-41.6% | $1.4M+313.5% | $1.9M+239.2% | $1.3M-33.3% | $1.8M+250.9% | $333K-18.0% | $561K | $1.9M |
| Free Cash Flow | -$15.7M-1.9% | -$25.2M-24.1% | -$10.5M+29.0% | -$10.0M+13.2% | -$15.4M-20.6% | -$20.3M-61.8% | -$14.8M | -$11.5M |
| Investing Cash Flow | $26.9M+336.3% | $21.8M+112.2% | $658K+102.2% | $9.5M-37.8% | $6.2M+87.1% | -$179.1M-2443.3% | -$29.7M | $15.2M |
| Financing Cash Flow | $1.8M+4188.1% | $623K-99.7% | $1.1M-98.1% | $2.7M+325.6% | $42K+139.3% | $211.1M+3518550.0% | $56.9M | -$1.2M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BBNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0%+5.2pp | 59.5%+8.6pp | 59.0%+1.8pp | 55.5%+2.1pp | 53.8%+0.1pp | 50.9%-4.8pp | 57.2% | 53.4% |
| Operating Margin | -79.9%+5.6pp | -87.9% | -50.2%+13.6pp | -62.5%+3.2pp | -85.5%-7.2pp | -105.7% | -63.8% | -65.7% |
| Net Margin | -73.1%-0.5pp | -79.3% | -41.9%+46.7pp | -52.1%+6.1pp | -72.6%+23.5pp | -162.5% | -88.6% | -58.3% |
| Return on Equity | -9.1%-3.5pp | -8.1%+1.1pp | -4.7% | -4.8% | -5.6% | -9.1% | N/A | N/A |
| Return on Assets | -8.0%-2.9pp | -7.2%+1.3pp | -4.1%+8.0pp | -4.3% | -5.1% | -8.5% | -12.1% | N/A |
| Current Ratio | 8.88-5.8x | 10.69-5.2x | 8.66+2.4x | 10.64 | 14.68 | 15.88 | 6.29-3.5x | N/A |
| Debt-to-Equity | 0.140.0x | 0.120.0x | 0.14 | 0.12 | 0.09 | 0.08 | N/A | N/A |
| Asset Turnover | 0.110.0x | 0.090.0x | 0.100.0x | 0.08 | 0.07 | 0.05 | 0.14 | N/A |
| FCF Margin | -48.9%+17.2pp | -91.3% | -32.8%+39.8pp | -36.7%+32.3pp | -66.1%+18.6pp | -115.1% | -72.6% | -69.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Beta Bionics, Inc. BBNX | FY2025 | $100.3M | -$73.2M | -73.0% | $951.1M | 66/100 |
| AdaptHealth Corp. AHCO | FY2025 | $3.2B | -$70.8M | -2.2% | $808.5M | 29/100 |
| SS Innovations International Inc. SSII | FY2025 | $42.5M | -$12.1M | -28.5% | $529.0M | 39/100 |
| Integra LifeSciences Holdings IART | FY2025 | $1.6B | -$516.8M | -31.6% | $1.0B | 37/100 |
| Establishment Labs Holdings Inc. ESTA | FY2025 | $211.1M | -$51.1M | -24.2% | $1.8B | 37/100 |
| InMode Ltd. INMD | FY2025 | $370.5M | $93.8M | 25.3% | $817.7M | 74/100 |
Where Beta Bionics, Inc. Ranks
Frequently Asked Questions
What is Beta Bionics, Inc.'s annual revenue?
Beta Bionics, Inc. (BBNX) reported $100.3M in total revenue for fiscal year 2025. This represents a 53.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Beta Bionics, Inc.'s revenue growing?
Beta Bionics, Inc. (BBNX) revenue grew by 53.9% year-over-year, from $65.1M to $100.3M in fiscal year 2025.
Is Beta Bionics, Inc. profitable?
No, Beta Bionics, Inc. (BBNX) reported a net income of -$73.2M in fiscal year 2025, with a net profit margin of -73.0%.
What is Beta Bionics, Inc.'s EBITDA?
Beta Bionics, Inc. (BBNX) had EBITDA of -$70.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Beta Bionics, Inc.'s gross margin?
Beta Bionics, Inc. (BBNX) had a gross margin of 55.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Beta Bionics, Inc.'s operating margin?
Beta Bionics, Inc. (BBNX) had an operating margin of -71.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Beta Bionics, Inc.'s net profit margin?
Beta Bionics, Inc. (BBNX) had a net profit margin of -73.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Beta Bionics, Inc.'s return on equity (ROE)?
Beta Bionics, Inc. (BBNX) has a return on equity of -25.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Beta Bionics, Inc.'s free cash flow?
Beta Bionics, Inc. (BBNX) recorded an outflow of $56.2M in free cash flow during fiscal year 2025. This represents a -8.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Beta Bionics, Inc.'s operating cash flow?
Beta Bionics, Inc. (BBNX) recorded an outflow of $50.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Beta Bionics, Inc.'s total assets?
Beta Bionics, Inc. (BBNX) had $328.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Beta Bionics, Inc.'s capital expenditures?
Beta Bionics, Inc. (BBNX) invested $5.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Beta Bionics, Inc. spend on research and development?
Beta Bionics, Inc. (BBNX) invested $34.8M in research and development during fiscal year 2025.
What is Beta Bionics, Inc.'s current ratio?
Beta Bionics, Inc. (BBNX) had a current ratio of 8.66 as of fiscal year 2025, which is generally considered healthy.
What is Beta Bionics, Inc.'s debt-to-equity ratio?
Beta Bionics, Inc. (BBNX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Beta Bionics, Inc.'s return on assets (ROA)?
Beta Bionics, Inc. (BBNX) had a return on assets of -22.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Beta Bionics, Inc.'s P/E ratio?
Beta Bionics, Inc. (BBNX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $951.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Beta Bionics, Inc.'s price-to-sales ratio?
Beta Bionics, Inc. (BBNX) trades at 8.0x sales, its market capitalization divided by revenue of $119.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $951.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Beta Bionics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Beta Bionics, Inc. (BBNX) held $264.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $50.9M over that year. Dividing the one by the other, the reported balance equals about 62 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Beta Bionics, Inc.'s Altman Z-Score?
Beta Bionics, Inc. (BBNX) has an Altman Z-Score of 12.75, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Beta Bionics, Inc.'s Piotroski F-Score?
Beta Bionics, Inc. (BBNX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Beta Bionics, Inc.'s earnings high quality?
Beta Bionics, Inc. (BBNX) reported a net loss of $73.2M while operations used $50.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Beta Bionics, Inc.?
Beta Bionics, Inc. (BBNX) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.